|Spread||Min. Trade||Leverage||Min. Deposit|
Vantage FX is an Australian firm which provides financial services to clients all around the world. It is based in Sydney, Australia but also has an office in London, United Kingdom as well. It provides services related to Binary or Forex trade and has won numerous awards in as a financial services provider.
Vantage FX offers its clients a friendly and interactive experience of the Forex market, and provides them with the latest tools and to take advantage of the foreign exchange market. The company provides services such as FX Copy, Meta Trader4 for Mac and Meta Trader4, since 2006 and has established itself as one of the primary dealers in the forex market in Australia.
Vantage FX deals in a variety of deposit currencies to make it easier for their clients to trade all over the world, they include:
United States Dollar
Great Britain Pound
This enables traders to trade globally with ease and gets a head start on their competition. Vantage FX has a team of Forex market experts that give expert analysis on the Forex industry, and how to use it to their own advantage. They also provide strategic advice and market analysis to their clients.
|Forex Broker Spreads »|
|Most Popular Articles »|
- Spanish Retail Sales Numbers Improve 8 views
- Ethisphere Names The Principal One of the World’s Most Ethical Companies 4 views
- Health Canada Issues Notice of Compliance for Gilead’s HarvoniTM (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 3 views
- Synchrony Financial and Pep Boys Extend Consumer Financing Program 3 views
- Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9 Million up 15.6% Over Last Year 2 views
- Appalachian Mountain Brewery Enters Distribution Agreement with Craft Brew Alliance 2 views
- Wipro Takes Minority Stake in Drivestream Inc. – Invests USD 5 Million 2 views
- Silver follows gold higher 2 views
- Pepperstone introduces ZARJPY pair 1 view
- Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma 1 view